Reference: Yagisawa, M., Foster, P. J., Hanaki, H., & Ōmura, S. (2021). Global trends in clinical studies of ivermectin in COVID-19. The Japanese Journal of Antibiotics, 74(1), 44-73. https://doi.org/xxxxxx Summary: The article reviews the global response to the COVID-19 pandemic, particularly the role of ivermectin as a potential treatment. Initially regarded as ineffective, ivermectin gained […]
Reference: Centres for Disease Control and Prevention. (2021, March 4). Understanding mRNA COVID-19 vaccines. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html Summary: mRNA vaccines represent a novel approach to immunisation against infectious diseases, including COVID-19. They work by instructing cells to produce a harmless piece of the virus’s spike protein, eliciting an immune response without introducing the live virus. This process
Reference: Bryant, A., Lawrie, T. A., Dowswell, T., Fordham, E., Hill, S., Mitchell, S., & Tham, T. (2021). The BIRD recommendation on the use of ivermectin for Covid-19: Proceedings and conclusions of the British Ivermectin Recommendation Development meeting held on the 20th February 2021 in Bath, United Kingdom. Evidence-Based Consultancy Medicine Ltd. Summary: The British
Reference: FDA. (2021). Vaccines and related biological products advisory committee meeting: February 26, 2021. Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. FDA Briefing Document. Summary: The FDA briefing document details the Emergency Use Authorization (EUA) request submitted by Janssen Biotech for the Ad26.COV2.S vaccine aimed at preventing COVID-19. This single-dose adenovirus vector vaccine demonstrated
Reference: British Ivermectin Recommendation Development. (2021). The BIRD recommendation on the use of ivermectin for Covid-19: Executive summary. Proceedings and conclusions of the British Ivermectin Recommendation Development meeting. Summary: The British Ivermectin Recommendation Development (BIRD) meeting, held on 20th February 2021 in Bath, aimed to evaluate ivermectin’s efficacy in treating and preventing Covid-19, especially in
Reference: Author. (2021). Case investigation form for AEFI serious, severe, cluster, AESI for all vaccines including COVID-19. Retrieved from [insert URL if available] Summary: The document is a Case Investigation Form designed to report Adverse Events Following Immunisation (AEFI) and Adverse Events of Special Interest (AESI) for all vaccines, including COVID-19. It is intended for
Reference: Kory, P., Meduri, G. U., Iglesias, J., Varon, J., & Marik, P. E. (2021). Review of the emerging evidence supporting the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. Front-Line COVID-19 Critical Care Alliance. Summary: This article by the Front Line COVID-19 Critical Care Alliance reviews the growing evidence supporting ivermectin’s effectiveness
Reference: Law, B. (2020). Priority List of COVID-19 Adverse Events of Special Interest: Quarterly Update December 2020. Safety Platform for Emergency Vaccines (SPEAC). Summary: The report provides a quarterly update on the Safety Platform for Emergency Vaccines (SPEAC) regarding Adverse Events of Special Interest (AESI) related to COVID-19. The December 2020 update includes three new
Reference: FLCCC Alliance. (2021). I-MASK+ prophylaxis & early outpatient treatment protocol for COVID-19. Retrieved from www.flccc.net Summary: The FLCCC Alliance’s I-MASK+ protocol provides guidelines for the prophylaxis and early outpatient treatment of COVID-19. It recommends the use of Ivermectin, along with Vitamin D3, Vitamin C, Quercetin, Zinc, Melatonin, and Aspirin for high-risk individuals and post-exposure
Reference: McCullough, P. A., Alexander, P. E., Armstrong, R., Arvinte, C., Bain, A. F., Bartlett, R. P., … & Zelenko, V. (2020). Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19). Reviews in Cardiovascular Medicine, 21(4), 517–530. https://doi.org/10.31083/j.rcm.2020.04.264 Summary: The article discusses a comprehensive approach to treat early ambulatory high-risk COVID-19